Clarity Pharmaceuticals (ASX:CU6) Shares Fall Today: What Is Keeping the Radiopharmaceutical Stock in Focus?

Sonal Goyal

06 November 2026 06:09 PM AEDT

Clarity Pharmaceuticals (ASX:CU6) Shares Fall Today: What Is Keeping the Radiopharmaceutical Stock in Focus?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Clarity Pharmaceuticals (ASX:CU6) traded at A$1.495 during the 6 November 2026 session, down 6.56%, the largest fall in its group.
The company reported a cash position of A$152.9 million at 30 September 2026.
The SECuRE cohort expansion met its recruitment target in October 2026, with topline data expected.

Clarity Pharmaceuticals (ASX:CU6) shares were quoted at A$1.495 during the 6 November 2026 trading session, down 6.56%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the quarterly activities report for the quarter ended 30 September 2026. Clarity develops copper-64 and copper-67 radiopharmaceuticals for cancer imaging and therapy.

Latest Developments

Quarterly Activities Report for the Quarter Ended 30 September 2026

The company reported a cash position of A$152.9 million at 30 September 2026. The cohort expansion of the Phase I/IIa SECuRE trial, evaluating 67Cu-SAR-bisPSMA with enzalutamide, achieved its recruitment target in October 2026, and topline data are anticipated. The company said the CLARIFY pivotal study results are intended to support an application to the US FDA.

About the Company

Clarity Pharmaceuticals is an ASX-listed radiopharmaceutical company headquartered in Sydney, developing products for prostate cancer.

Business Overview

Clarity's pipeline includes copper-67 and copper-64 PSMA-targeted agents for imaging and therapy, with clinical programs in prostate cancer.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Radiopharmaceutical developers depend on clinical data and regulatory progress, and their shares react strongly to trial news.

Risks to Watch

Trial results are not yet available, and regulatory submissions depend on pivotal data. Competition from other PSMA agents is intense, and the company's funding depends on its cash position.

Catalysts on Watch

Investors may follow the SECuRE topline data, the CLARIFY pivotal results and any regulatory filing timetable.

Final Takeaways

Clarity Pharmaceuticals (ASX:CU6) traded lower on 6 November 2026, with the largest fall in its group. Its quarterly update covers the cash position and the SECuRE recruitment milestone.

FAQs

Q: What was the CU6 share price on 6 November 2026?

A: Clarity shares were quoted at A$1.495 during the trading session, down 6.56%.

Q: What was the cash position?

A: A$152.9 million at 30 September 2026.

Q: What milestone was reached?

A: Recruitment for the SECuRE cohort expansion in October 2026.

Q: When are topline data expected?

A: The release says topline data are anticipated, without a fixed date.

Q: Is the session move linked to the update?

A: No. The quarterly was for the period ended 30 September 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.